Published in Biotech Law Weekly, June 4th, 2004
The company also reported gross profit of $10.6 million, a 46% increase from the first quarter of 2003, and a net loss of $884,000 or $0.02 per share, a 62% improvement from the net loss in the first quarter of 2003.
In addition, TriPath Imaging's commercial operations segment was profitable for the sixth consecutive quarter.
In the first quarter of 2004, worldwide sales of reagents and disposables increased 37% from the first quarter of 2003, and 3% over the fourth quarter of 2003, accounting for 74% of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2004-06-04)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.